[Effect of urolithin A on production of interleukins 6 and 10 by immune cells from patients with MS and healthy donors].
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kukushkina A D, Rogovsky V S, Boyko A N
Аннотация
MATERIAL AND METHODS: The effect of urolithin A on stimulated production of interleukin (IL)-6 and interleukin-10 by peripheral blood mononuclear cells (PBMCs) and macrophages in patients with MS and healthy donors was evaluated using enzyme immunoassay.
RESULTS: Basal and lipopolysaccharide-stimulated production of IL-10 PBMCs in patients with MS is lower than in healthy donors. In contrast, basal and stimulated production of IL-6 by PBMCs is higher in patients with MS compared to healthy donors. Urolithin A at 5 μM contributed to an increase in the production of IL-10 by PBMCs both in MS patients (by an average of 28%) and in healthy donors. Urolithin A also caused a decrease in the macrophage production of IL-6 in healthy donors (by an average of 10%) and MS patients.
CONCLUSION: Given the beneficial immunotropic effect of urolithin A, this metabolite of the intestinal microbiota can be considered a promising compound for further study in patients with MS, including in clinical placebo-controlled studies.
Оригинал публикации
[Effect of urolithin A on production of interleukins 6 and 10 by immune cells from patients with MS and healthy donors].
OBJECTIVE: To study the effect of urolithin A on cytokine production in multiple sclerosis (MS) patients and healthy donors.
MATERIAL AND METHODS: The effect of urolithin A on stimulated production of interleukin (IL)-6 and interleukin-10 by peripheral blood mononuclear cells (PBMCs) and macrophages in patients with MS and healthy donors was evaluated using enzyme immunoassay.
RESULTS: Basal and lipopolysaccharide-stimulated production of IL-10 PBMCs in patients with MS is lower than in healthy donors. In contrast, basal and stimulated production of IL-6 by PBMCs is higher in patients with MS compared to healthy donors. Urolithin A at 5 μM contributed to an increase in the production of IL-10 by PBMCs both in MS patients (by an average of 28%) and in healthy donors. Urolithin A also caused a decrease in the macrophage production of IL-6 in healthy donors (by an average of 10%) and MS patients.
CONCLUSION: Given the beneficial immunotropic effect of urolithin A, this metabolite of the intestinal microbiota can be considered a promising compound for further study in patients with MS, including in clinical placebo-controlled studies.